secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABBOTT LABORATORIES (ABT)
CIK:        0000001800
Form:       8-K
Filed at:   2026-04-17T23:59:59+00:00
Accession:  0001104659-26-044892
Event type: litigation
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abbott reaches settlement in shareholder derivative suit over infant formula; governance reforms, up to $15.85M fees
--------------------------------------------------------------------------------

- Settlement of consolidated derivative action alleging fiduciary breaches and securities violations related to infant formula recall.
- Abbott to adopt corporate governance reforms; no admission of wrongdoing.
- Lead plaintiffs' counsel seeks up to $15.85M in fees/expenses and service awards up to $15,000 each.
- Court approval hearing set for June 4, 2026; shareholder objections due by May 18, 2026.
- Dismissal with prejudice of all claims; governance enhancements to improve compliance oversight.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800/000110465926044892/0001104659-26-044892-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800/000110465926044892/tm2611915d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-044892

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer